United Therapeutics Corporation (NASDAQ: UTHR) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Earnings and Valuation

This table compares United Therapeutics Corporation and ANI Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
United Therapeutics Corporation $1.63 billion 3.17 $1.01 billion $8.57 13.90
ANI Pharmaceuticals $158.12 million 4.26 $59.01 million $0.46 125.93

United Therapeutics Corporation has higher revenue and earnings than ANI Pharmaceuticals. United Therapeutics Corporation is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

United Therapeutics Corporation has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for United Therapeutics Corporation and ANI Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United Therapeutics Corporation 3 6 2 0 1.91
ANI Pharmaceuticals 0 1 2 0 2.67

United Therapeutics Corporation presently has a consensus price target of $134.70, indicating a potential upside of 13.10%. ANI Pharmaceuticals has a consensus price target of $67.33, indicating a potential upside of 16.23%. Given ANI Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than United Therapeutics Corporation.

Insider and Institutional Ownership

56.0% of ANI Pharmaceuticals shares are owned by institutional investors. 7.8% of United Therapeutics Corporation shares are owned by company insiders. Comparatively, 31.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares United Therapeutics Corporation and ANI Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
United Therapeutics Corporation 24.18% 20.96% 16.03%
ANI Pharmaceuticals 3.35% 22.70% 11.48%

Summary

ANI Pharmaceuticals beats United Therapeutics Corporation on 8 of the 13 factors compared between the two stocks.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.